UPDATED – Comitology Written Consultation: Standing Committee on medicinal products for human use

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

List of safety concerns per approved Risk Management Plan (RMP) of active substances per product

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Opening remarks by Commissioner Kyriakides at the launch of the MEP Interest Group on antimicrobial resistance

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Agenda: EMA Committee for Advanced Therapies (CAT) (19 – 21 February 2020)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

UPDATED – Agenda: Pharmacovigilance Risk Assessment Committee (PRAC) (30 September – 3 October 2019 )

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

UPDATED – Comitology Written Consultation: Standing Committee on medicinal products for human use

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Written Answer to a Question: Spinal muscular atrophy (SMA) — Zolgensma — Novartis

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

UPDATED – Comitology Written Consultation: Standing Committee on medicinal products for human use

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Agenda: EMA Committee for Orphan Medicinal Products (COMP) (18 – 20 February 2020)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

OPP Meeting Summary: Health Council – COVID-19 outbreak (13 February 2020)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

EU PSUR Work Sharing Summary Assessment Report: Highly refined fish oil (eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) dl-αTocopherol), Glycerol, Purified egg phosphatide

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Minutes: CMDh meeting with representatives of Interested Parties (13 November 2019)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

UPDATED – Agenda: EMA Pharmacovigilance Risk Assessment Committee (PRAC) (10 – 13 February 2020)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

UPDATED – Comitology Written Consultation: Standing Committee on medicinal products for human use

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Press Release: Cooperation is key to counter the COVID-19 outbreak: the Council adopts conclusions

The Council today adopted conclusions on COVID-19. The conclusions welcome the EU’s effective response to the challenges arising from the outbreak of Novel coronavirus and urge member states to take the necessary measures to enhance their cooperation. They also call on the Commission to examine ways of facilitating member states’ access to personal protective equipment and to evaluate the consequences of global health threats for the availability of medicines within the EU.

Stakeholder Press Release: Call for a Mutual Recognition Agreement on Good Manufacturing Practice (GMP) in the Context of Ambitious and Comprehensive EU-UK Future Relationship Negotiations

By European Federation of Pharmaceutical Industries and Associations

The pharmaceutical industry in Europe has worked to support the EU27 and UK to reach an agreement that will allow patients to receive medicines and medical technologies without disruption and provide long term co-operation between the EU and the UK in areas such as research, clinical trials, pharmacovigilance and access to talent. Our industry’s stance remains that the EU and UK should have the closest possible relationship for pharmaceuticals, prioritising the health of citizens and the uninterrupted supply of medicines.

Minutes: EMA Paediatric Committee (PDCO) Meeting (23 – 26 July 2019)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

UPDATED – EMA Paediatric Committee (PDCO)(17-20 September 2019)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Agenda: Working Party on Pharmaceuticals and Medical Devices (18 February 2020)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

UPDATED – Comitology Written Consultation: Standing Committee on medicinal products for human use

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

UPDATED – Agenda: Pharmacovigilance Risk Assessment Committee (PRAC) (2 – 5 September 2019)

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

Stakeholder Publication: Lung Cancer Europe: 2020 Position Paper – Disparities and challenges in access to lung cancer diagnosis and treatment across Europe

By Lung Cancer Europe

Lung cancer is responsible for nearly 1 in 5 cancer related deaths in Europe, yet it remains a cancer that is underfunded and underrepresented. Previous research has demonstrated that many people impacted by lung cancer face disparities in access to diagnostics, treatment and care.

To mark World Cancer Day, LuCE has released its latest position paper which identifies disparities and challenges in access to lung cancer diagnostics and treatment across Europe. Data were collected through 34 healthcare professionals/researchers, 16 pharmaceutical companies and LuCE members (patient organizations).

UPDATED – Comitology Written Consultation: Standing Committee on medicinal products for human use

Have you logged into your account? If you are an OPP customer or have free trial access and you can't view this content please click login at the top of the screen.  If you are not an OPP subscriber, create a free account now and get started with 30 days free Enterprise access to read this page and use our range of policy tools. Sign up takes under 2 minutes, the 30 day free access ends automatically, and we don't ask for any credit card details.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. Cookies help you create your Policy Newsfeed for example. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close